Clinical characterization and molecular mechanisms of statin myopathy
Authors:
- Peter P TothPTPeter P Toth
- Charles R HarperCHCharles R Harper
- Terry A JacobsonTJTerry A Jacobson
- 1 August 2008
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 6 (7) , 955-969
Abstract
Myopathy has been reported in a small percentage of statin-treated patients for the past 30 years, but the etiologic mechanisms for inducing muscle injury have not yet been fully characterized. Statin-induced myopathy is now understood to be a heterogeneous condition that may be due to: mechanisms of the drug itself; interactions with other drugs; or genetic, metabolic and immunological vulnerabilities in individual patients. In some cases, statins may unmask latent conditions (e.g., asymptomatic baseline myopathy) that predispose patients to muscle toxicity. The definitions, epidemiology, clinical features, risk factors and proposed mechanisms of statin-induced myopathy are reviewed. Muscle metabolism can be adversely impacted by statin therapy, including changes in fatty acid oxidation, possibly reduced coenzyme Q(10) biosynthesis, and increased myocyte protein degradation via the activity of atrogin-1 and the ubiquitin-proteasome pathway. Statin therapy may also activate a variety of autoimmune phenomena that potentiate myocellular injury. Improving our understanding of statin-induced myopathy is a high clinical priority given the large number of patients eligible for statin therapy and the fact that the development of myalgia and myopathy are leading reasons cited by patients for statin discontinuation.Keywords
This publication has 58 references indexed in Scilit:
- Efficacy and Tolerability of Fluvastatin XL 80 mg Alone, Ezetimibe Alone, and the Combination of Fluvastatin XL 80 mg With Ezetimibe in Patients With a History of Muscle-Related Side Effects With Other StatinsThe American Journal of Cardiology, 2008
- The Role of Coenzyme Q10 in Statin-Associated MyopathyJACC, 2007
- Genetic determinants of statin intoleranceLipids in Health and Disease, 2007
- Final Conclusions and Recommendations of the National Lipid Association Statin Safety Assessment Task ForceThe American Journal of Cardiology, 2006
- An Assessment of Statin Safety by Muscle ExpertsThe American Journal of Cardiology, 2006
- Statin Safety and Drug Interactions: Clinical ImplicationsThe American Journal of Cardiology, 2006
- Changes in Ubiquitin Proteasome Pathway Gene Expression in Skeletal Muscle With Exercise and StatinsArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemiaAmerican Heart Journal, 2005
- The cerivastatin withdrawal crisis: a “post-mortem” analysisHealth Policy, 2004
- ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of StatinsStroke, 2002